Tilia Fiduciary Partners’s Ginkgo Bioworks DNA Stock Holding History

Tilia Fiduciary Partners’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-11	Closed	-$715	–	521
2022 Q4	$715	Hold	11	–	–	﹤0.01%	481
2022 Q3	$1K	Hold	11	–	–	﹤0.01%	492
2022 Q2	$1K	Hold	11	–	–	﹤0.01%	506
2022 Q1	$2K	Sell	11 -4	-27%	-$779	﹤0.01%	501
2021 Q4	$5K	Buy	+15	New	+$7.13K	﹤0.01%	470

Other funds holding DNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Tilia Fiduciary Partners's DNA Position: Q1 2023 in Review

Tilia Fiduciary Partners sold out of Ginkgo Bioworks (DNA) in Q1 2023, closing a stake of 11 shares — an estimated $715 sold.

Tilia Fiduciary Partners first reported a position in DNA in Q4 2021 and held it in 5 quarters. The position peaked at $5K in Q4 2021. 313 funds tracked by Wall St. Rank hold DNA as of Q1 2023.

Tilia Fiduciary Partners reported no remaining Ginkgo Bioworks position as of Q1 2023 after selling out during the quarter.
Tilia Fiduciary Partners sold 11 Ginkgo Bioworks shares in Q1 2023, an estimated $715.
Tilia Fiduciary Partners first reported a position in Ginkgo Bioworks in Q4 2021 and held it in 5 quarters.
Tilia Fiduciary Partners's Ginkgo Bioworks position peaked at $5K in Q4 2021.
313 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2023.

Based on Tilia Fiduciary Partners's 13F filing for Q1 2023, filed 10 May 2023.